Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alglucosidase Alfa Dosing Frequency Reduction in Elderly LOPD (TRIPOD)
NCT06575829Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Replacement Enzymes
01
Overview
A Phase 4 trial of alglucosidase alfa in Pompe disease, sponsored by Erasmus MC. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT06575829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575829.